DexTech Medical AB (XSAT:DEX) ROC %: -67.66% (As of Mar. 2026)


XSAT:DEX DexTech Medical AB XSAT:DEX
32 GF Score
Price kr10.30
! 3 Warning Signs
View Full Analysis

What is DexTech Medical AB ROC %?

DexTech Medical AB XSAT:DEX 32 ROC % is -67.66% as of Mar. 2026. GuruFocus rates XSAT:DEX with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. DexTech Medical AB's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -67.66%.

As of today (2026-06-26), DexTech Medical AB's WACC % is 21.20%. DexTech Medical AB's ROC % is -60.75% (calculated using TTM income statement data). DexTech Medical AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.


DexTech Medical AB  (XSAT:DEX) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, DexTech Medical AB's WACC % is 21.20%. DexTech Medical AB's ROC % is -60.75% (calculated using TTM income statement data). DexTech Medical AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


DexTech Medical AB ROC % Related Terms


DexTech Medical AB ROC % Historical Data

* Premium members only.

The historical data trend for DexTech Medical AB's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexTech Medical AB ROC % Chart

DexTech Medical AB Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -111.29 -135.79 -71.54 -51.87 -48.63

DexTech Medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -48.10 -59.17 -52.57 -65.66 -67.66
XSAT:DEX
32GF Score
DexTech Medical AB XSAT:DEX
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexTech Medical AB ROC % Calculation

DexTech Medical AB's annualized Return on Capital (ROC %) for the fiscal year that ended in Jun. 2025 is calculated as:

ROC % (A: Jun. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jun. 2024 ) + Invested Capital (A: Jun. 2025 ))/ count )
=-5.318 * ( 1 - 0% )/( (11.611 + 10.261)/ 2 )
=-5.318/10.936
=-48.63 %

where

DexTech Medical AB's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-6.992 * ( 1 - 0% )/( (10.108 + 10.561)/ 2 )
=-6.992/10.3345
=-67.66 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -67.66% mean?
DexTech Medical AB (XSAT:DEX) has a ROC % of -67.66% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on DexTech Medical AB and its competitors.
Is DexTech Medical AB's ROC % too high?
DexTech Medical AB's current ROC % is -67.66%. Overall, DexTech Medical AB has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does DexTech Medical AB's ROC % compare to VRTX and REGN?
DexTech Medical AB's ROC % of -67.66% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on DexTech Medical AB and its competitors. DexTech Medical AB's current ROC % is -67.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexTech Medical AB stock overvalued right now?
DexTech Medical AB (XSAT:DEX) has a current ROC % of -67.66%. The current ROC % is -67.66%. DexTech Medical AB's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For DexTech Medical AB (XSAT:DEX), the current ROC % is -67.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DexTech Medical AB Business Description

Address Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex.
32GF Score

Get the complete analysis for XSAT:DEX

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.30
Price